CCHE57357 has arranged the first annual international conference that addresses updates &challenges of pediatric hematologic malignancies in cooperation with the Egyptian Pediatric Hematology Oncology Society EPHOS

(Early this month CCHE57357 arranged the first annual international which spotted the light on challenges and updates of pediatric hematology malignancies supervised by Dr. AlaaEl Hadda, head of the pediatric oncology department at CCHE57357.  The agenda of the three-day conference involved instructive sessions on recent practices and challenges in pediatric hematologic malignancies, infectious diseases hematopoietic stem cell transplantation, and cell therapy. The discussion has also encompassed two workshops on clinical pharmacy and clinical nutrition related to pediatric cancer patients.

Hospital 57357 organized the first annual international conference on challenges and updates of pediatric hematologic malignancies presided over by Dr. Alaa El Haddad, Head of Hospital 57357’s pediatric oncology department. The conference lasted three days (Oct.6-Oct.8) and included several educational sessions related to the current practice and challenges in pediatric hematologic malignancies, infectious diseases, hematopoietic stem cell transplantation, and cell therapy. It also included two workshops related to clinical nutrition and clinical pharmacy with a special focus on practice in pediatric cancer patients. 

Attending the conference and leading the sessions were a stellar group of experts and distinguished speakers from different leading institutions in the U.S and Egypt from Hospital 57357, Cairo university, Ain Shams University, and Alexandria university. A group of professionals within the field of pediatric oncology have led and attended the event and are also renowned lecturers from various institutions in the U.S CCHE57357, Cairo university, Ain Shams University, and Alexandria university.   

This meeting was a golden opportunity for professionals to explore breakthroughs in malignant hematology and connect with national and international experts and exchange experiences in the field.

The event was a good fortune for the experts to discover the innovations taking place in malignant hematology to get linked with local and worldwide professionals and to share experiences in the field. 

 Throughout the 3 day’s meeting, malignant hematology was one of the main focuses of the sessions with discussions around acute lymphoblastic leukemia which is one of the most common malignancies in children. Different therapies of AML were also tackled including targeted and immune therapies as well as treatments for severe and relapsing cases.

  A distinctive session that focused on all topics related to Haploidentical stem cell transplant was also included and tackled several topics such as treating side effects of BMT and required tests to select the best donor to reduce failure incidences.

During the three-day event, malignant hematology was a highlighted topic with deliberations about acute lymphoblastic leukemia, as a prevailing type of cancer in children. Various treatments of AML were also addressed including targeted and immune therapies and those for relapsing patients. Moreover, a unique session on all related aspects to the Haploidentical stem cell transplant was Involved and has addressed some issues including treating drawbacks of BMT, and needed tests to make the proper selection of donors to decrease the failure occurrence. 

During the conference, discussions took place on the role of health economics and outcomes research in evidence-based decision-making, comparing results of different world pediatric lymphoma treatment protocols and ways of treating rare lymphoma cases. 

The significance of health economics and consequences of research in empirical decision making, analyzing results of various international pediatric lymphoma treatment procedures and ways of handling uncommon lymphoma cases.

With respect to clinical pharmacy, topics discussed included pharmaceutical compounding in pediatric oncology, how to get trusted medical information, advanced pediatric oncology pharmacy practice, and how to create a unit for drug compounding in a healthcare setting.  

Regarding the clinical pharmacy, among discussed issues involved in the event were obtaining reliable medical data, pharmaceutical compounding in pediatric oncology, updated performances in pediatric oncology pharmacy, and setting up a specialized unit for drug compounding within a healthcare venue.   

 Presentations included also novel ways in the treatment of hemophilia, diagnosis and management of acute lymphoblastic leukemia ALL in down syndrome patients, the role of genes in management of ALL. lectures have also highlighted new methods in curing hemophilia, diagnosing& controlling of ALL in down syndrome cases, the role played by genes in treating ALL.

 As for clinical nutrition, workshops presented the role of clinical nutrition in treatment of children with cancer, guidelines for nutrition of cancer patients, principles of enteral and parenteral nutrition, challenges with GIT surgery, and the nutrition diet for BMT patients.

Concerning clinical nutrition, its seminars highlighted the role played by proper clinical nutrition in curing pediatric oncology patients, strategies of nutrition of cancer patients, concepts of eternal and parenteral nutrition, and challenges with GIT surgery besides the nourishment regime for BMT patients.

Dr. Emad Mousa, pediatric oncology consultant in 57357, spoke about lymphoma, what was done in 57357 lately and the application of two treatment protocols, the first was applied in USA, then Hospital 57357 changed it to a European treatment protocol with amazing results since March 2019. The protocol details and a comparison of treatment results between Egypt and Germany were presented during the conference. Dr. Mousa asserted that scientific exchange is very important to be acquainted with new findings about treatment and diagnosis of leukemia.

“what was lately done in CCHE57357 and the application of two treatment protocols of lymphoma, the first was applied in the USA, then the hospital changed it to European treatment protocol with amazing results since March 2019”, Said Dr. Emad Mousa in his talk about lymphoma. The fine points About the treating program and the differences between the treating results between Egypt& Germany were introduced at the conference.  “The scientific exchange is very important to be acquainted with new findings about treatment and diagnosis of leukemia” Dr. Mousa added.

The conference sessions also included a presentation by Dr. Shadi Fadl from the Faculty of Medicine, Alexandria University, about Hodgkin lymphoma. Dr Scott Howard, from the USA outlined the reasons for non-survival in some cases of children with cancer in countries with middle income.

The conference talks have involved some seminars given by oncology experts on Hodgkin lymphoma by Dr Sahdi Fadl, from the University of Alexandria, and Dr. Scott Howard, from the USA who has determined the details of treatment failure of some oncology patients in middle-income countries. 

Through scientific exchange with major international centers and universities, Hospital 57357 pursues to improve and develop diagnostic and treatment methods in pediatric cancer, aiming to raise cure rates, to realize our vision of being a unique icon of change towards a cancer-free childhood.

CCHE 57357 has succeeded to update its diagnostic and curing strategies in pediatric cancer due to its  global scientific networking with universities and centers in an attempt to increase treatment rates and to achieve the hospital’s vision of being a unique icon of change towards a cancer-free childhood.